Pharma News

The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.

The specialty pharmaceutical company, Valeant Pharmaceuticals International, Inc., through its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, has received FDA approval for its new drug application for Jublia...

Amgen has appointed David W. Meline as executive vice president and chief financial officer (CFO), effective July 21, 2014. He will be responsible for Amgen's finance and investor relations operations, reporting to Robert A. Bradway , chairman and...

Actavis plc has finalized its previously announced agreement with Zydus Pharmaceuticals USA Inc. to settle all outstanding patent litigation related to Zydus' generic version of Asacol  HD (mesalamine) delayed-release tablets.  The terms...

Merck & Co. Inc, has agreed to acquire the biopharmaceutical company Idenix Pharmaceuticals Inc. for $24.50 per share in cash or approximately $3.85 billion. Idenix is engaged in the discovery and development of medicines for treating human...

arGEN-X, a clinical-stage biopharmaceutical company focused on developing differentiated therapeutic antibodies for treating cancer and severe autoimmune diseases, has formed a long-term strategic alliance with Shire Pharmaceuticals. The multi-year...

Citing family reason, Marijn Dekkers, CEO of Bayer AG, will step down at the end of 2016. To ensure continuity in key aspects of Bayer's future development, Bayer's supervisory board has appointed Werner Baumann, currently chief...

Adaptimmune Limited, an UK-based biotechnology company developing T-cell receptor (TCR) engineered T-cells to treat cancer, has entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development...

Zydus Pharmaceuticals USA Inc., part of the the pharmaceutical company Zydus Cadila, has issued a voluntary Class II recall of 10,200 bottles of promethazine hydrochloride tablets, USP, 25 mg, 100 prescription only, due to the presence of...

Actavis plc it has entered into an agreement with Cephalon, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Nuvigil  (armodafinil tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg). Nuvigil is a...